Adjuvant
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Jan 28, 2022 → Oct 28, 2022
NCT ID
NCT05032352About Adjuvant
Adjuvant is a pre-clinical stage product being developed by Insight Molecular Diagnostics for Carcinoma, Non-Small-Cell Lung. The current trial status is terminated. This product is registered under clinical trial identifier NCT05032352. Target conditions include Carcinoma, Non-Small-Cell Lung.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05032352 | Pre-clinical | Terminated |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung